Pfizer Announces an Independent Medical Education Grant RFP

Relapsed/Refractory Multiple Myeloma
Competitive Grant Program - internal Pfizer review process

I. BackgroundPfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives(e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet
medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP)
that provides detail regarding a general area of interest, sets timelines for review and approval, and uses
an internal Pfizer review process to make final grant decisions. Organizations are invited to submit anapplication addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is
responsible for the design, implementation, and conduct of the independent initiative supported by thegrant. Pfizer must not be involved in any aspect of project development, nor the conduct of theindependent education program.

3
Relapsed/Refractory
Multiple Myeloma

II. Eligibility
Geographic Scope:

United States, Western Europe, Japan, Singapore, Canada and Brazil (NOTE:Countries in red included in RFP re-release June 30, 2022)

Applicant EligibilityCriteria•

The following may apply: medical, nursing, allied health, and/or
pharmacy professional schools; healthcare institutions (both large andsmall); professional associations and medical societies; medical
education companies; and other entities with a mission related tohealthcare professional education and/or healthcare improvement.

•If the project involves multiple departments within an institution and/or
between different institutions / organizations / associations. all institutions
must have a relevant role and the requesting organization must have akey role in the project.

•For projects offering continuing education credit, the requestingorganization must be accredited.

Date RFP Issued•

July 1, 2022

Clinical Area•

Oncology-Hematology-Myeloma

III. Requirements

General Area of Interestfor this RFP:

Projects that will be considered for Pfizer support will focus on increasing
healthcare professional understanding of BCMA-directed therapies(BCMAxCD3 bi-specifics; BCMA-ADC; BCMA – CAR-T cells) in
relapsed/refractory multiple myeloma, including:•Mechanisms of action•

Available clinical data – efficacy insights and side effect profiles•

Overview of experiences and potential for sequencing of BCMAdirected treatments•

Clinical risk factors for the development of treatment-specific AEs•

Use of prognostic biomarkers (with focus on cytogenetics/GEP) inclinical practice•Role of sBCMA on this therapeutic class•

Role of MRD in response assessment and therapy management•

Mechanisms of drug-resistance/loss of response with emergingtreatments•

Therapy management1

3
Relapsed/Refractory
Multiple Myeloma

All activity formats will be considered under this RFP (live in-person, livevirtual, enduring courses, online communities, digital, social, etc.)
It is not our intent to support clinical research projects. Projects evaluating
the efficacy of therapeutic or diagnostic agents will not be considered.

Target Audience:•Hematologists/Oncologists and other healthcare professionals involvedin the care of people with multiple myeloma

Expected Approximate
Monetary Range ofGrant Applications:•Individual projects requesting up to $250,000 will be considered. The
estimated total available budget related to this RFP is $800,000.

•Smaller grant requests for local or regional activities or for more limited
audiences are also encouraged.

Key Dates:•

RFP release date: July 1, 2022•

Grant Application due date: August 8, 2022
Please note the deadline is 23:59 Eastern Standard Time (e.g., NewYork, GMT -5).

How to Submit:•Anticipated Grant Award Notification Date: September 9, 2022

•Grants will be distributed following a fully executed agreement.

•Anticipated Approximate Project Start and End Dates: October 2022 toJune 2023 (Maximum project length of 20 months)•Please go to https://www.cybergrants.com/pfizer/knowledge and sign in.
First-time users should click “Create your password”. [Note: there areindividual portals for each grant application type (e.g., knowledge, LOI,
research full proposal, and QI full proposal). Please be sure to use the URLabove.]•Click the “Start A New Knowledge Gap Application” button.

•In the application:•oFor the question “What type of request are you submitting?” selectResponse to a Request for Proposal (RFP)o

For the question “Are you replying to a Request for Proposal (RFP)as part of the Competitive Grant Program?” select YesoSelect the following Competitive Grant Program Name:
2022 Onc G: Relapsed Refractory Multiple MyelomaoSelect the following Primary Area of Interest: Multiple Myeloma

Requirements for submission:
Complete all required sections of the online application and upload yourproject proposal (see Appendix) in the General RFP Submission field.
2

3
Relapsed/Refractory
Multiple Myeloma•If you encounter any technical difficulties with the website, please click
the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not
be reviewed by the committee.

Questions:•If you have questions regarding this RFP, please direct them in writing
to the Grant Officer, Amanda Kaczerski(Amanda.Kaczerski@pfizer.com), with the subject line
“Relapsed/Refractory Multiple Myeloma June 2022.”

Grant Agreements:•If your grant is approved, your institution will be required to enter into awritten grant agreement with Pfizer. Please click here to view the coreterms of the agreement.

•Pfizer has drafted the terms of these agreements to be balanced andreasonable and to further the goals of both parties. Negotiating grant
agreements requires significant resources, so please ensure that yourinstitution (including your legal department) is able and willing to abideby these terms before proceeding with submission of your application
as they will need to be accepted in their entirety.

Review and Approval
Process•

Grant requests received in response to a general RFP are reviewed byPfizer to make final grant decisions.

Mechanism by which
Applicants will beNotified:••

All applicants will be notified via email by the dates noted above.
Applicants may be asked for additional clarification during the review
period.

3

3
Relapsed/Refractory
Multiple Myeloma

Appendix A

General RFP Submission Requirements
Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins.
Note there is a 15-page limit exclusive of references. Please include the following:Goals and Objectives••

Briefly state the overall goal of the project.
List the objectives you plan to meet with your project, in terms of learningand expected outcomes.

Needs Assessment for
the Project•

Include a description of your organization’s needs assessment for this
proposed project which may include a quantitative baseline datasummary, initial metrics, or a project starting point (please cite data ongap analyses or relevant patient-level data that informs the statedobjectives) in your target area.

Target Audience•Describe the primary audience(s) targeted for this project. Indicate whom
you believe will directly benefit from the project outcomes. Indicate
whether the project is addressing a global or regional/local population.
Describe the overall population size as well as the size of your sample
population.

Project Design andMethods•

Describe the planned project, the educational approach, and the way theplanned methods address the established need.

Innovation•

Explain what measures you have taken to assure that this project isoriginal and does not duplicate other projects or materials alreadydeveloped. Describe how this project builds upon existing work, pilot
projects, or ongoing projects developed either by your institution or otherinstitutions.

Evaluation andOutcomes•In terms of the metrics used for the needs assessment, describe how
your organization will determine if the gap was addressed for the target
group. Identify the sources of data your organization anticipates using to
make the determination. Describe how your organization is expected tocollect and analyze the data. Explain the method used to control for otherfactors outside this project (e.g., use of a control group or comparison
with baseline data). Quantify the amount of change expected from thisproject in terms the target audience. Describe how your organization will
determine if the target audience was fully engaged in the project.

Dissemination Plan•

Describe how the project may have extended benefit beyond the grant.
Will the teaching materials be made available to others to use? Will
there be tools or resources that are made publicly available beyond the43
Relapsed/Refractory
Multiple Myeloma

initial project. Describe how the project outcomes might be broadly
disseminated.

Anticipated ProjectTimeline•Provide an anticipated timeline for your project including project start/enddates.

Additional Information•

If there is any additional information you feel Pfizer should be aware ofconcerning the importance of this project, please summarize here.

Organization Detail•

Describe the attributes of the institutions/organizations that will support
and facilitate the execution of the project, the leadership of the proposed
project, and the specific role of each institution in the proposed project.

Budget Narrative•

Please include a budget narrative that describes in greater detail the line
items specified in the budget submitted within the application•

While estimating your budget please keep the following items in mind:oo

Independent Medical Education Grants awarded by GMG cannot be
used to purchase therapeutic assets (prescription or nonprescription).
Overhead rates of up to 28% of the total proposed project budget
may be supported by Pfizer.

5